Global Gene Delivery Technologies Market by Application (Cell Therapy, Gene Therapy), by Mode (AAV, Retrovirus, Lentivirus), by Method (In-vivo, Ex-vivo) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global gene delivery technology market was valued at USD 2.6 Billion in 2020. It is projected to grow at a compound annual rate (CAGR of 15.1%) between 2021 and 2028. Cell and gene therapies have not only revolutionized the treatment of intractable and genetic diseases, but also helped to reshape the entire pharmaceutical industry. Nearly 990 companies were involved in R&D and the commercialization of advanced therapies by the end of 2019. Market forces for gene delivery technologies are driven by the constantly changing landscape of advanced therapies.

The technological advances in nanotechnology and physical tech have led to extensive research into advanced methods of delivering physical genes such as optoporation and sonoporation. These techniques are becoming more popular due to their non-toxic nature and shortness. These factors will increase the use of the products in the market, and thus encourage organic revenue growth for the operating players.

Thermo Fisher Scientific spent USD 180 million in May 2020 to double its viral vector manufacturing capabilities. Next Generation Manufacturing Canada also provided funding of USD 1.89 million in August 2019 to support the development and manufacturing of advanced lentiviral vectors. This investment and financing will help to increase the organic revenue.

Many new players have entered the market due to the expanding market for gene delivery technologies. The market is growing rapidly because the players in the industry are using different business strategies. Many companies have begun to seek support from CMOs in order to produce viral vectors. Oxford Biomedica, for example, signed a Clinical and Commercial Supply Agreement in May 2020 with AstraZeneca to manufacture the adenovirus vector-based COVID-19 vaccine.

The majority of delivery technologies have been used in research settings. Very few are being applied for clinical purposes. This is due to the technical and efficiency challenges that each mode of delivery presents. Therefore, efforts towards developing more efficient technology are encouraged. Physical techniques, in particular, require breakthroughs for their use in clinical settings.

Mode Insights

Due to the success of Yescarta and Kymriah, the biological vectors segment dominated gene delivery technology market. It accounted for the largest share of revenue at 58.0% in 2020. Since the approval of the first virus vector-based gene therapy products, viral-vectors have attracted a lot of attention. The acceptance of viral vectors as the main delivery method has been supported by the exponential growth in viral vector-based R&D programs.

Chemical methods have been used because of the many clinical problems associated with viral systems. Polyethyleneimine (PEI), and polyamidoamine dindrimers have been recognized as alternative viral gene delivery systems because of their ability to combat the challenges associated with viral systems.

Their lower transfection efficiency compared to biological and chemical methods results in the lowest penetration. Low cell viability is another major shortcoming of electroporation-based physical methods. These drawbacks can be overcome by market players who are looking to increase their revenue share.

Application Insights

Gene therapy dominated the market for gene delivery technologies and accounted for 33.0% of the total revenue share in 2020. This segment has seen a rise in gene-based therapies and consequently, more clinical research initiatives. The segment's growth has been accelerated by the increasing acceptance of gene therapy products around the world.

Second-generation DNA vaccines have the potential to induce more potent humoral or cellular responses. This has made it possible to investigate this method of disease management, both in therapeutic and preventative areas. This will likely drive the adoption of gene editing tools to develop vaccines.

This group is expected to benefit significantly from the recent SARS-CoV-2 outbreak. Nearly 25 research groups have been working towards the development virus vector-based vaccines that will stop the spread of SARS. Similar efforts are being made by around 20 research groups to study genetic instructions in order to develop nucleic acid vaccines.

Method Insights

The ex-vivo method was the dominant market leader in gene delivery technologies in 2020 with a 41.0% revenue share. This is due to several advantages, such as its ability to evaluate transduction efficiency before implantation and less immunogenic reactions. It is also highly useful in research settings due to its high transduction efficiency.

In vivo gene therapy, while the preferred method of gene transduction is in vivo, can be difficult in situations where very targeted delivery is needed. Targeted delivery errors can cause an immune response and less penetration into this market segment for gene delivery technologies.

Scientists are making concentrated efforts to speed up R&D in this area. In March 2020, Oregon Health and Science University, which is based in the U.S., used the gene-editing tool Crispr Cas9 to modify DNA for treatment of a form of genetic blindness within the human body. This segment is expected to grow in a lucrative way.

Regional Insights

North America was the dominant market for gene delivery technology and had the highest revenue share at 39.4% in 2020. Numerous clinical trials are being conducted to determine if gene therapies can be used as a viable treatment for certain cancers, genetic conditions, or HIV/AIDS. A significant number of companies involved in the commercialization and supply of gene delivery technology are also based in the U.S. These factors have helped to make the United States the dominant region in the gene delivery technology market.

Horizon 2020 calls saw the introduction of several new collaboration research and innovation projects. This project includes viral vector-based gene therapy trials in rare conditions. This will encourage the adoption of gene-delivery technologies in Europe. Asia Pacific countries are also emerging as strong competitors in this area.

Asia is a popular target for drug-makers due to its large population and low operating costs. China is also recognized as a hub for gene and cell therapy development. It has been ranked second in the world in terms of clinical trials, with over 1,000 trials currently underway or being conducted between 2017 and 2019. China's strong policy support is key to its growth in this area.

Market Share Insights & Key Companies

It is expected that the increasing interest in gene delivery technologies by both public and private investors will accelerate the entry of new players to the market. To increase their market presence, major players are taking strategic steps such as licensing, mergers and acquisitions, and partnering. The market for gene delivery technology has seen many mergers and acquisitions in the last few years.

Merck, for example, announced in May 2020 that it had acquired Themis, a developer of vaccines and immuno-modulation therapies to increase its vaccine development capabilities for the SARS/CoV-2 vaccine program. In May 2019, Thermo Fisher Scientific also acquired Brammer Bio. Brammer Bio is a CDMO that manufactures viral vectors for gene therapy. End-users, such as gene therapy developers and cell scientists, are also involved in strategic alliances for their therapy development with vector suppliers, which is a key factor driving market growth. The market leader in gene delivery technologies is:

• Thermo Fisher Scientific, Inc.

• QIAGEN

• Horizon Discovery Group Co.

• OriGene Technologies, Inc.

• Oxford Biomedica

• SignaGen Laboratories

• Vectalys

• Takara Bio Inc.

• Bio-Rad Laboratories Inc.

• System Biosciences llc

• Promega Corporation

• Hoffmann-La Roche AG

• Sirion-Biotech GmbH

• Catalent Inc.

Up Market Research published a new report titled “Gene Delivery Technologies Market research report which is segmented by Application (Cell Therapy, Gene Therapy), by Mode (AAV, Retrovirus, Lentivirus), by Method (In-vivo, Ex-vivo), By Players/Companies Thermo Fisher Scientific Inc, Catalent Inc, Takara Bio Inc, SignaGen Laboratories, Horizon Discovery Group Co, Bio-Rad Laboratories Inc, Hoffmann-La Roche AG, System Biosciences llc, Promega Corporation, QIAGEN, Oxford Biomedica, OriGene Technologies Inc, Vectalys, Sirion-Biotech GmbH”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Gene Delivery Technologies Market Report Segments:

The market is segmented by Application (Cell Therapy, Gene Therapy), by Mode (AAV, Retrovirus, Lentivirus), by Method (In-vivo, Ex-vivo).

Gene Delivery Technologies Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Gene Delivery Technologies Market

Overview of the regional outlook of the Gene Delivery Technologies Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Gene Delivery Technologies Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Gene Delivery Technologies Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Cell Therapy

                2. Gene Therapy

                1. AAV

                2. Retrovirus

                3. Lentivirus

                1. In-vivo

                2. Ex-vivo

9. Market scenario by region, sub-region, and country.
10. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
11. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
12. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Gene Delivery Technologies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Gene Delivery Technologies Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.